Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259649
Status:
COMPLETED
Last Update Posted:
2011-07-04
First Post:
2005-11-26
Brief Title:
Prospective Survey of Menstrual Migraine Prevention With Eletriptan
Sponsor:
University of Pittsburgh
Organization:
University of Pittsburgh
Study Overview
Official Title:
Assessment and Prevention of Menstrual Migraine Phase 1-prospective Survey of Self-identified Menstrual Migraine Phase 2-prevention of Menstrual Migraine With Relpax
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Women are followed prospectively for 3 months recording headaches other symptoms and menstrual periods Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months
Detailed Description:
Women are followed prospectively for 3 months recording headaches other symptoms and menstrual periods Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None